Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: SkyQuest | PRODUCT CODE: 1373870

Cover Image

PUBLISHER: SkyQuest | PRODUCT CODE: 1373870

Global Monoclonal Antibody Therapy Market Size, Share, Growth Analysis, By Type(Murine Antibodies, Chimeric Antibodies), By Application(Oncology, Autoimmune Diseases) - Industry Forecast 2023-2030

PUBLISHED:
PAGES: 157 Pages
DELIVERY TIME: 3-5 business days
SELECT AN OPTION
Single User License
USD 5300
Multiple User License
USD 6200
Enterprise License
USD 7100

Add to Cart

Global Monoclonal Antibody Therapy Market size was valued at USD 133.8 billion in 2021 and is poised to grow from USD 143.57 billion in 2022 to USD 252.26 billion by 2030, growing at a CAGR of 7.3% in the forecast period (2023-2030).

One of the primary drivers of the global monoclonal antibody therapy market is the increasing prevalence of chronic diseases, such as cancer, autoimmune disorders, and cardiovascular diseases. Monoclonal antibody therapies have shown promising results in the treatment of these conditions, leading to their growing adoption. Additionally, the aging population and the rise in lifestyle-related diseases have further contributed to the market growth. Technological advancements have enabled the production of highly specific and effective antibodies, increasing their therapeutic efficacy. Additionally, the growing focus on personalized medicine and targeted therapies has further fueled the demand for monoclonal antibody therapies.

Top-down and bottom-up approaches were used to estimate and validate the size of the global Monoclonal Antibody Therapy Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined by using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Monoclonal Antibody Therapy Market Segmental Analysis

The global monoclonal antibody therapy market is segmented based on type, application, and region. Based on type, the market can be segmented into Murine Antibodies, Chimeric Antibodies, Humanised Antibodies, and Fully Human Antibodies. Based on application, the market is segmented into Oncology, Autoimmune Diseases, Infectious Diseases, Inflammatory Conditions and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Global Monoclonal Antibody Therapy Market Dynamics

Drivers of the Global Monoclonal Antibody Therapy Market

Advancements in Biotechnology and Genetic Engineering

Significant progress in biotechnology and genetic engineering has played a pivotal role in the development of advanced monoclonal antibody therapies. These advancements have facilitated the engineering of antibodies with improved specificity, efficacy, and reduced side effects. Through techniques such as genetic manipulation, researchers can optimise monoclonal antibodies for specific targets, enhancing their therapeutic potential. These breakthroughs have broadened the range of applications for monoclonal antibody therapies and increased their success rates.

Restraints in the Global Monoclonal Antibody Therapy Market

Potential Side Effects and Safety Concerns

Like any medical intervention, monoclonal antibody therapies carry the potential for side effects and safety concerns. Some patients may experience reactions related to the administration of the therapy, such as infusion-related reactions. Additionally, there is a possibility of immunogenicity, where the patient's immune system may mount an immune response against the therapy. Off-target effects, where the therapy may interact with unintended targets in the body, can also occur. It is crucial to closely monitor and address these safety concerns to ensure patient well-being, maintain confidence in the therapy, and adhere to regulatory standards. Continuous monitoring, robust safety assessment, and clear communication of potential risks are vital in managing these concerns effectively.

Market Trends of Global Monoclonal Antibody Therapy Key

Increasing Adoption and Development of Personalised and Targeted Therapies: Monoclonal antibody therapies have gained significant momentum in the treatment of various diseases, including cancer, autoimmune disorders, and infectious diseases. Personalised medicine approaches, such as companion diagnostics, genetic profiling, and biomarker identification, are being integrated into the development and prescription of monoclonal antibody therapies. This trend allows for a more precise and tailored treatment approach, maximising therapeutic efficacy while minimising adverse effects.

Product Code: SQMIG35A2527

Table of Contents

  • Executive Summary
    • Market Overview
    • Wheel of Fortune
  • Research Methodology
    • Information Procurement
    • Secondary & Primary Data Sources
    • Market Size Estimation
    • Market Assumptions & Limitations
  • Parent Market Analysis
    • Market Overview
    • Market Size
    • Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
  • Key Market Insights
    • Technology Analysis
    • Pricing Analysis
    • Supply Chain Analysis
    • Value Chain Analysis
    • Ecosystem of the Market
    • IP Analysis
    • Trade Analysis
    • Startup Analysis
    • Raw Material Analysis
    • Innovation Matrix
    • Pipeline Product Analysis
    • Macroeconomic Indicators
    • Top Investment Analysis
    • Key Success Factor
    • Degree of Competition
  • Market Dynamics & Outlook
    • Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
    • Regulatory Landscape
    • Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers
    • Skyquest Special Insights on Future Disruptions
  • Political Impact
  • Economic Impact
  • Social Impact
  • Technical Impact
  • Environmental Impact
  • Legal Impact
  • Global Monoclonal Antibody Therapy Market by Type
    • Market Overview
    • Murine Antibodies
    • Chimeric Antibodies
    • Humanised Antibodies and Fully Human Antibodies
  • Global Monoclonal Antibody Therapy Market by Application
    • Market Overview
    • Oncology
    • Autoimmune Diseases
    • Infectious Diseases
    • Inflammatory Conditions and Others.
  • Global Monoclonal Antibody Therapy Market Size by Region
    • Market Overview
    • North America
  • USA
  • Canada
    • Europe
  • Germany
  • Spain
  • France
  • UK
  • Rest of Europe
    • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
    • Latin America
  • Brazil
  • Rest of Latin America
    • Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA
  • Competitive Landscape
    • Top 5 Player Comparison
    • Market Positioning of Key Players, 2021
    • Strategies Adopted by Key Market Players
    • Top Winning Strategies
  • By Development
  • By Company
  • By Year
    • Recent Activities in the Market
    • Key Companies Market Share (%), 2021
  • Key Company Profiles
    • Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • Johnson & Johnson (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • Novartis International AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • Pfizer Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • Merck & Co., Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • Amgen Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • AstraZeneca PLC (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • Bristol Myers Squibb Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • AbbVie Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • Eli Lilly and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • Biogen Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • Regeneron Pharmaceuticals, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • Moderna, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • BioNTech SE (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • Alexion Pharmaceuticals, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • Gilead Sciences, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • CSL Limited (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!